Search by drug, manufacturer, or indication

Displaying 981 - 990 of 1165

Harvoni (ledipasvir/sofosbuvir)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Chronic Hepatitis C

Last updated February 17, 2017

Daklinza (daclatasvir)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Chronic Hepatitis C

Last updated February 17, 2017

Epclusa (sofosbuvir/velpatasvir)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Chronic Hepatitis C

Last updated February 17, 2017

Sunvepra (asunaprevir)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Chronic Hepatitis C

Last updated February 17, 2017

Zepatier (elbasvir/grazoprevir)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Chronic Hepatitis C

Last updated February 17, 2017

Technivie (ombitasvir/paritaprevir/ritonavir)

Status:

Concluded without agreement

Manufacturer:

AbbVie Corporation

Indication:

Chronic Hepatitis C (genotype 4)

Last updated February 17, 2017

Sovaldi (sofosbuvir)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Chronic Hepatitis C

Last updated February 17, 2017

Plegridy (peginterferon beta-1a)

Status:

Concluded with an LOI

Manufacturer:

Biogen Canada Inc.

Indication:

Multiple Sclerosis, Relapsing

Last updated February 14, 2017

Strensiq (asfotase alfa)

Status:

Concluded without agreement

Manufacturer:

Alexion Pharma GmbH

Indication:

Pediatric-onset hypophosphatasia

Last updated February 9, 2017

Naglazyme (galsulfase)

Status:

Negotiations were not pursued

Manufacturer:

BioMarin Pharmaceutical Inc.

Indication:

Mucopolysaccharidosis VI

Last updated January 31, 2017